Therapies and Diagnostics for Ovarian Cancer Market Global Scenario, Market Size, Outlook, Trend, and Forecast, 2016 – 2025

TABLE OF CONTENTS

Chapter 1        Prefix

1.1    Market Scope

1.2    Report Description

1.3    Research Methodology

1.3.1     Primary Research

1.3.2     Secondary Research

1.3.3     In-house Data Modeling

Chapter 2        Executive Summary

2.1   Global Therapies and Diagnostics for Ovarian Cancer Market Year-on-Year Growth, 2020 – 2028 (%)

Chapter 3        Market Outline

3.1    Market Inclination, Trend, Outlook and Viewpoint

3.2    Market Share Analysis: Company’s Competitive Scenario

3.3    Value Chain Analysis

3.4    Porter’s Five Forces Analysis

3.5    Market Dynamics

3.5.1     Drivers

3.5.1.1     Impact Analysis

3.5.2     Restraints

3.5.2.1     Impact Analysis

3.5.3     Opportunities

Chapter 4        Global Therapies and Diagnostics for Ovarian Cancer Market by Diagnosis: Market Size and Forecast, 2019 – 2028

4.1    Overview

4.2  Epithelial Ovarian Tumors

4.2.1   Current Trend and Analysis

4.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.2.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

4.3  Germ Cell Tumors

4.3.1   Current Trend and Analysis

4.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.3.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

4.4  Stromal Tumors

4.4.1   Current Trend and Analysis

4.4.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.4.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

Chapter 5        Global Therapies and Diagnostics for Ovarian Cancer Market: by Cancer Type: Market Size and Forecast, 2019 – 2028

5.1  Overview

5.2  Primary Peritoneal Cancer

5.2.1   Current Trend and Analysis

5.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

5.3  Sages of Ovarian Cancer

5.3.1   Current Trend and Analysis

5.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

5.4  Prognosis

5.4.1   Current Trend and Analysis

5.4.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

Chapter 6        Global Therapies and Diagnostics for Ovarian Cancer Market by Geography: Market Size and Forecast, 2019 - 2028

6.1  Overview

6.1.1   Global Therapies and Diagnostics for Ovarian Cancer Market Year-on-Year Growth, by region 2020 – 2028 (%)

6.2  North America

6.2.1   Current Trend and Analysis

6.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

6.2.3   U.S.

6.2.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.2.3.2        By Diagnosis

6.2.3.3        By Cancer Type

6.2.4   Canada

6.2.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.2.4.2        By Diagnosis

6.2.4.3        By Cancer Type

6.2.5   Mexico

6.2.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.2.5.2        By Diagnosis

6.2.5.3        By Cancer Type

6.3    Europe

6.3.1   Current Trend and Analysis

6.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

6.3.3   UK

6.3.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.3.3.2        By Diagnosis

6.3.3.3        By Cancer Type

6.3.4   Russia

6.3.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.3.4.2        By Diagnosis

6.3.4.3        By Cancer Type

6.3.5   France

6.3.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.3.5.2        By Diagnosis

6.3.5.3        By Cancer Type

6.3.6   Italy

6.3.6.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.3.6.2        By Diagnosis

6.3.6.3        By Cancer Type

6.3.7   Germany

6.3.7.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.3.7.2        By Diagnosis

6.3.7.3        By Cancer Type

6.3.8   Rest of Europe

6.3.8.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.3.8.2        By Diagnosis

6.3.8.3        By Cancer Type

6.4    Asia-Pacific

6.4.1   Current Trend and Analysis

6.4.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

6.4.3   China

6.4.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.4.3.2        By Diagnosis

6.4.3.3        By Cancer Type

6.4.4   India

6.4.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.4.4.2        By Diagnosis

6.4.4.3        By Cancer Type

6.4.5   Japan

6.4.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.4.5.2        By Diagnosis

6.4.5.3        By Cancer Type

6.4.6   Rest of Asia-Pacific

6.4.6.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.4.6.2        By Diagnosis

6.4.6.3        By Cancer Type

6.5    RoW

6.5.1   Current Trend and Analysis

6.5.2   Market Size and Forecast

6.5.3   South America

6.5.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.5.3.2        By Diagnosis

6.5.3.3        By Cancer Type

6.5.4   Middle East

6.5.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.5.4.2        By Diagnosis

6.5.4.3        By Cancer Type

6.5.5   Africa

6.5.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

6.5.5.2        By Diagnosis

6.5.5.3        By Cancer Type

Chapter 7        Company Profiles

7.1  Abbvie Inc.

7.1.1     Company Overview

7.1.2     Product Portfolio

7.1.3     Business Strategies

7.1.4     Financials

7.1.5     Recent Developments

7.2  Astra Zeneca

7.2.1     Company Overview

7.2.2     Product Portfolio

7.2.3     Business Strategies

7.2.4     Financials

7.2.5     Recent Developments

7.3  Bristol – Myers Squibb

7.3.1     Company Overview

7.3.2     Product Portfolio

7.3.3     Business Strategies

7.3.4     Financials

7.3.5     Recent Developments

7.4  Celgene Corp.

7.4.1     Company Overview

7.4.2     Product Portfolio

7.4.3     Business Strategies

7.4.4     Financials

7.4.5     Recent Developments

7.5  Clovis Oncology

7.5.1     Company Overview

7.5.2     Product Portfolio

7.5.3     Business Strategies

7.5.4     Financials

7.5.5     Recent Developments

7.6  Eli Lilly & Company

7.6.1     Company Overview

7.6.2     Product Portfolio

7.6.3     Business Strategies

7.6.4     Financials

7.6.5     Recent Developments

7.7  GlaxoSmithKline

7.7.1     Company Overview

7.7.2     Product Portfolio

7.7.3     Business Strategies

7.7.4     Financials

7.7.5     Recent Developments

7.8  Hikma Pharmaceuticals Plc

7.8.1     Company Overview

7.8.2     Product Portfolio

7.8.3     Business Strategies

7.8.4     Financials

7.8.5     Recent Developments

7.9  Janssen Pharmaceutical Plc

7.9.1     Company Overview

7.9.2     Product Portfolio

7.9.3     Business Strategies

7.9.4     Financials

7.9.5     Recent Developments

7.10       Merck & Co. Inc.

7.10.1   Company Overview

7.10.2   Product Portfolio

7.10.3   Business Strategies

7.10.4   Financials

7.10.5   Recent Developments

7.11       Myriad Genetics Inc.

7.11.1   Company Overview

7.11.2   Product Portfolio

7.11.3   Business Strategies

7.11.4   Financials

7.11.5   Recent Developments

7.12       Novartis AG

7.12.1   Company Overview

7.12.2   Product Portfolio

7.12.3   Business Strategies

7.12.4   Financials

7.12.5   Recent Developments

7.13       Pfizer Inc.

7.13.1   Company Overview

7.13.2   Product Portfolio

7.13.3   Business Strategies

7.13.4   Financials

7.13.5   Recent Developments

7.14       Quest Diagnostic Inc.

7.14.1   Company Overview

7.14.2   Product Portfolio

7.14.3   Business Strategies

7.14.4   Financials

7.14.5   Recent Developments

7.15       Roche Holding AG

7.15.1   Company Overview

7.15.2   Product Portfolio

7.15.3   Business Strategies

7.15.4   Financials

7.15.5   Recent Developments

7.16       Tesaro, Inc.

7.16.1   Company Overview

7.16.2   Product Portfolio

7.16.3   Business Strategies

7.16.4   Financials

7.16.5   Recent Developments